{"filings":[{"id":1940559,"accession_number":"0001193125-26-323652","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-07-29T20:05:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.","Phase 3 VANQUISH-1 (4,500 patients) and VANQUISH-2 (1,000) for subcutaneous VK2735 fully enrolled.","Oral VK2735 Phase 3 trial initiation expected in Q4 2026; maintenance dosing data due Q3 2026.","Phase 1 trial of amylin agonist VK3019 initiated in Q2 2026 after IND clearance.","Appointed Hubert Chen, M.D., as CMO; Dorothy Gemmell to board; cash $502M at June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669196,"accession_number":"0001193125-26-239535","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-05-26T20:48:01+00:00","items":["5.07","9.01"],"status":"ready","headline":"Viking Therapeutics annual meeting elects two Class II directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["J. Matthew Singleton elected with 28.6M votes for; S. Kathryn Rouan with 22.0M for.","Ratification of CBIZ CPAs as independent auditor for FY 2026 approved (78.4M for, 1.2M against).","Advisory vote on named executive officer compensation passed (30.0M for, 12.8M against).","Quorum achieved with 80.1M shares (69.1% of outstanding) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94059,"accession_number":"0001193125-26-191487","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.","Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.","Maintenance dosing study for VK2735 is ongoing with data expected in 3Q26; the study explores weekly, every-other-week, and monthly dosing.","IND filed for novel amylin agonist VK3019; Phase 1 trial initiation planned for 2Q26.","First quarter 2026 cash position was $603 million, with R&D expenses of $150.2 million and net loss of $158.3 million, compared to $45.6 million net loss in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106145,"accession_number":"0001193125-26-046536","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).","Cash & investments $706M at Dec 31, 2025 vs $903M a year earlier; burn reflects Phase 3 ramp.","VANQUISH-1 (obesity) enrollment completed >4,500 ahead of schedule; VANQUISH-2 (obesity+diabetes) near full.","Oral VK2735 to advance to Phase 3 in 3Q26 after FDA end-of-Phase 2 meeting; maintenance dosing data due 3Q26.","IND filing for novel amylin agonist planned in 1Q26; Phase 1 maintenance study fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122436,"accession_number":"0001193125-25-246775","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.","Cash, equivalents and short-term investments totaled $715M as of Sept 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH-1 for VK2735 in obesity expects enrollment completion by end of 2025; VANQUISH-2 by Q1 2026.","Phase 2 VENTURE-Oral study showed up to 12.2% mean weight loss after 13 weeks; up to 97% achieved ≥5% weight loss.","Maintenance dosing study of VK2735 initiated; plans to file IND for dual amylin/calcitonin agonist in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139132,"accession_number":"0001607678-25-000003","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).","Up to 97% of VK2735 subjects achieved ≥5% weight loss vs 10% placebo; up to 80% achieved ≥10% vs 5% placebo.","Safety: 99% of GI-related TEAEs mild/moderate; discontinuation due to AE in 20% VK2735 vs 13% placebo.","Statistically significant weight loss seen in all doses >15 mg from Week 1 through Week 13.","Exploratory maintenance arm: weight loss sustained after down-titration from 90 mg to 30 mg daily for 7 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139131,"accession_number":"0000950170-25-097885","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.","Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.","Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.","Amylin agonist program progressing; IND filing planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156661,"accession_number":"0000950170-25-077865","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.","Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.","Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.","Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156660,"accession_number":"0000950170-25-057337","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.","Cash, cash equivalents & short-term investments totaled $852M at March 31, 2025, down from $903M at Dec 31, 2024.","Phase 3 trials for subcutaneous VK2735 in obesity expected to begin in 2Q25; Phase 2 VENTURE-Oral Dosing trial fully enrolled, data expected 2H25.","Signed broad manufacturing agreement with CordenPharma for VK2735 API and fill/finish capacity; prepayments from 2025-2028 credited against future orders.","Dual amylin/calcitonin receptor agonist (DACRA) program IND planned for 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156659,"accession_number":"0000950170-25-057323","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Viking Therapeutics appoints CBIZ as independent auditor after Marcum resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum resigned April 18, 2025, after CBIZ acquired its attest business.","Audit committee appointed CBIZ as auditor for FY2025 on April 22, 2025.","No disagreements or reportable events with Marcum in FY2023 or FY2024.","Company will file revised proxy for May 20, 2025 annual meeting to reflect CBIZ in Proposal 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175084,"accession_number":"0000950170-25-036820","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.","CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.","Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.","Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175083,"accession_number":"0000950170-25-014464","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.","Cash, cash equivalents and short-term investments of $903M as of Dec 31, 2024, up from $362M a year earlier.","Initiation of Phase 3 studies for subcutaneous VK2735 in obesity planned for 2Q25 after FDA End-of-Phase 2 meeting.","Phase 2 VENTURE-Oral trial of VK2735 tablet underway in ~280 obese subjects; data expected 2H25.","Phase 2b VOYAGE in MASH: VK2809 showed MASH resolution rates up to 75% vs 29% placebo, and fibrosis improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192036,"accession_number":"0000950170-24-120267","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.","100% of subjects on 100 mg oral VK2735 reached ≥5% weight loss vs. 0% placebo; GI events mostly mild.","Phase 2 VENTURE: 94% of weight loss maintained 4 weeks post-final dose; supports once-monthly dosing.","78% of prediabetic patients on VK2735 shifted to normoglycemic over 13 weeks vs. 29% on placebo.","Oral Phase 2 to start by year-end 2024; injectable Phase 3 design to be discussed with FDA this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192035,"accession_number":"0000950170-24-116642","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.","Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.","End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.","Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.","Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208511,"accession_number":"0000950170-24-086039","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.","Oral VK2735 Phase 2 trial in obesity expected to start in 4Q24; 28-day weight loss up to 5.3% from baseline.","VK2809 met secondary endpoints in NASH/fibrosis; NASH resolution rates 63-75% vs 29% placebo; End-of-Phase 2 meeting 4Q24.","Q2 net loss $22.3M ($0.20/share) vs $19.2M ($0.19) year ago; R&D expenses rose to $23.8M.","Cash and investments $942M at June 30, 2024, up from $362M at year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226203,"accession_number":"0000950170-24-068297","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).","Fibrosis improvement ≥1 stage with no NASH worsening: 44-57% for VK2809 vs 34% placebo (p<0.05 for 5 mg and 10 mg QOD, combined p=0.03).","Combined endpoint (NASH resolution + fibrosis improvement) achieved by 40-50% vs 20% placebo (p<0.05 for 5 mg, 10 mg QOD, combined p=0.003).","Liver fat reduction at 52 weeks: mean relative change -37% to -55%; ≥30% reduction in 64-88% of VK2809 patients (all p<0.0001 vs placebo).","GI adverse events similar to placebo; discontinuation rates low; LDL-C reductions of 20-25% vs placebo (p<0.01)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226202,"accession_number":"0000950170-24-063707","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.","2024 Equity Incentive Plan approved (48.5M for, 19.3M against).","2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).","Advisory say-on-pay approved (63.2M for, 4.5M against).","Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226201,"accession_number":"0000950170-24-047567","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.","Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.","Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.","Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.","Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245270,"accession_number":"0000950170-24-036151","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735","Placebo-adjusted mean weight loss up to 3.3%; up to 57% of treated subjects achieved ≥5% weight loss vs 0% placebo","VK2735 well-tolerated with low GI adverse events; no serious adverse events reported","Company plans Phase 2 trial in obesity for second half of 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245269,"accession_number":"0000950170-24-024878","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Viking Therapeutics closes $632.5M public offering of 7.44M shares at $85.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 7,441,650 shares at $85.00 each, including full exercise of underwriters' option for 970,650 additional shares.","Gross proceeds of approximately $632.5 million before underwriting discounts and offering expenses.","Net proceeds will fund continued development of VK2809, VK2735, VK0214 programs and general corporate purposes.","Joint book-running managers: Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel, Truist Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245268,"accession_number":"0000950170-24-023838","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Viking Therapeutics prices $550M public offering of 6.47M shares at $85/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$550M from 6.47M shares at $85; underwriters have 30-day option for 970,650 additional shares.","Net proceeds to fund development of VK2809, VK2735, VK0214 programs and general corporate purposes.","Offering expected to close March 4, 2024; Morgan Stanley & Leerink Partners lead underwriters.","Directors and executive officers subject to 90-day lock-up until May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245267,"accession_number":"0000950170-24-020616","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.","Up to 88% of VK2735-treated patients achieved ≥10% weight loss vs 4% for placebo.","No weight loss plateau observed; reductions progressive through week 13.","Well-tolerated: 92% of drug-related TEAEs mild/moderate; low discontinuation (13% vs 14% placebo).","Company plans FDA meeting to discuss next steps; oral formulation data expected this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245266,"accession_number":"0000950170-24-012199","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.","Cash & equivalents $362.1M vs $155.5M year-end 2022, funding pipeline milestones.","Phase 2 VENTURE (VK2735, obesity) topline results expected in 1Q24; oral VK2735 Phase 1 data also 1Q24.","Phase 2b VOYAGE (VK2809, NASH) 52-week histology results expected in 1H24.","Phase 1b VK0214 for X-ALD results expected in 1H24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262720,"accession_number":"0000950170-23-055209","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.","Cash & equivalents $376M at Sept 30, 2023, vs $155.5M at Dec 31, 2022 (includes $287.5M public offering).","Phase 2 VENTURE trial of VK2735 (GLP-1/GIP agonist) for obesity fully enrolled (n=176); results expected 1H24.","Phase 1 oral VK2735 study ongoing; data expected 1Q24. Phase 2b VOYAGE (VK2809 for NASH) histology results expected 1H24.","Phase 1b VK0214 for X-ALD enrolling; enrollment completion expected 4Q23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279911,"accession_number":"0000950170-23-034741","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.","VK2809 showed significant reductions in LDL-C and triglycerides; Phase 2b 52-week biopsy results expected 1H24.","Phase 2 study of obesity candidate VK2735 to start 3Q23; Phase 1 oral formulation data expected 4Q23.","Net loss $19.2M ($0.19 loss/share) vs $17.4M ($0.23) in Q2 2022; R&D spend $13.9M, G&A $9.8M.","Ended Q2 with $393M cash, boosted by $288M stock offering; cash runway through multiple catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298400,"accession_number":"0000950170-23-027965","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Viking Therapeutics shareholders reelect directors, ratify auditor, reject officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected J. Matthew Singleton and S. Kathy Rouan as Class II directors to serve until 2026 annual meeting.","Ratified Marcum LLP as independent registered public accounting firm for FY2023 (76.6M for, 173k against).","Advisory vote on named executive officer compensation passed (53.4M for, 1.3M against, 22.1M broker non-votes).","Amendment to certificate of incorporation for officer exculpation under Delaware law failed; received 52.8M votes for (53% of outstanding), needed 66.7% of all shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298399,"accession_number":"0000950170-23-021359","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Viking Therapeutics amends bylaws for universal proxy rules and enhanced disclosure","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended and restated bylaws effective May 9, 2023.","Amendments require stockholders nominating directors to comply with SEC Rule 14a-19 universal proxy rules.","Enhanced disclosure requirements for director nominations and business proposals by stockholders.","Stockholders soliciting proxies must use a proxy card color other than white; white reserved for Board.","Eliminated requirement to make stockholder list available during meetings, consistent with Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298398,"accession_number":"0000950170-23-014788","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.","Cash and investments $135.7M at March 31; pro forma with $287.5M offering totals ~$406M.","VK2735 Phase 1: up to 7.8% mean weight loss from baseline (6% placebo-adjusted); half-life 170-250h; no discontinuations for GI AEs.","Phase 2b VOYAGE study of VK2809 for NASH fully enrolled; primary endpoint data expected in Q2 2023.","Phase 1 oral formulation of VK2735 initiated; data expected 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298397,"accession_number":"0000950170-23-011636","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Viking Therapeutics closes $287.5M public offering of 19.8M shares at $14.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $287.5 million from 19,828,300 shares at $14.50 per share.","Underwriters' option to purchase 2,586,300 additional shares exercised in full.","Net proceeds to fund VK2809, VK2735, VK0214 programs and general corporate purposes.","William Blair & Co. served as lead book-runner; Raymond James as joint book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318613,"accession_number":"0000950170-23-011443","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.","Net proceeds to fund development programs VK2809, VK2735, VK0214 and for general R&D and working capital.","Lead bookrunners: William Blair and Raymond James; co-managers: BTIG, Oppenheimer, H.C. Wainwright, Maxim, Roth, Laidlaw.","Offering expected to close on April 3, 2023, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318612,"accession_number":"0000950170-23-010112","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.","Randomized, double-blind, placebo-controlled study evaluating daily oral doses for 28 days.","Primary objective: safety and tolerability; exploratory measures include body weight and plasma glucose.","Top-line data anticipated in the second half of 2023.","Prior subcutaneous Phase 1 showed up to 7.8% mean weight loss; Phase 2 for subcutaneous formulation planned for mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318611,"accession_number":"0000950170-23-010108","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.","No hypoglycemia reported; 98% of adverse events mild/moderate; one SAE (gallstone obstruction) in a subject with history of cholelithiasis.","VK2735 half-life ~170-250 hours; plans to evaluate higher doses with longer titration in Phase 2.","Phase 2 trial in obesity expected to initiate in mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318610,"accession_number":"0001564590-23-001611","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.","Full-year 2022 net loss $68.9M ($0.90/shr) vs $55.0M ($0.71/shr) in 2021; cash $155M (down from $202M).","Enrollment completed for Phase 2b VOYAGE study of VK2809 in NASH/fibrosis; topline data expected Q2 2023.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; initial data expected Q1 2023.","Phase 1b study of VK0214 in X-ALD enrolling; data expected H2 2023; cash runway beyond key milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336847,"accession_number":"0001564590-22-035271","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q3 net loss $15.8M ($0.21/sh); cash $155M; three clinical data reads in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.8M ($0.21 per share) vs $13.2M ($0.17) in Q3 2021; nine-month net loss $49.3M ($0.64) vs $42.6M ($0.55).","Cash, cash equivalents and short-term investments $155M, down from $202M at year-end 2021.","VK2809 VOYAGE Phase 2b for NASH/fibrosis enrollment to finish Q4 2022; primary endpoint data 1H 2023.","Phase 1 data for dual GLP-1/GIP agonist VK2735 expected early 2023; Phase 1b VK0214 for X-ALD data in 1H 2023.","R&D expense $12.0M in Q3 vs $10.8M a year ago; G&A $4.2M vs $2.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354223,"accession_number":"0001564590-22-026689","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.","Cash, cash equivalents and short-term investments at $169M as of June 30, 2022.","VK2809 Phase 2b VOYAGE study for NASH/fibrosis; enrollment completion expected in 4Q 2022.","Phase 1 study of dual GLP-1/GIP agonist VK2735 ongoing; initial results expected by year-end 2022.","FDA clinical hold on VK0214 Phase 1b for X-ALD lifted; dosing to resume, data expected 1H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372150,"accession_number":"0001564590-22-021417","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors; Foehr received 17.1M votes for, Rowland 16.3M.","Ratified Marcum LLP as independent auditor for FY2022 with 50.7M votes for, 0.4M against, 66K abstentions.","Advisory vote on named executive officer compensation passed with 25.2M for, 1.7M against, 0.9M abstain.","Broker non-votes of about 23.4M shares on director elections and say-on-pay due to uninstructed shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372149,"accession_number":"0001564590-22-016110","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.","Cash and investments $184.9M at March 31, 2022, down from $202.1M at Dec 31, 2021.","Phase 2b VOYAGE study of VK2809 for NASH expects to complete enrollment in 2H22.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; results expected by year-end.","VK0214 for X-ALD on clinical hold, expects to submit requested preclinical data to FDA in 2Q22."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391033,"accession_number":"0001564590-22-004406","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q4 net loss $12.4M; clinical hold on VK0214; cash $202.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.4M ($0.16/share) for Q4 2021 vs $10.9M ($0.15) year ago; FY net loss $55.0M ($0.71) vs $39.5M ($0.54).","Cash, equivalents, short-term investments $202.1M at Dec 31, 2021, down from $248.4M a year ago.","FDA placed Phase 1b trial of VK0214 (X-ALD) on clinical hold; expects to submit requested preclinical data in Q2 2022.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 initiated; data expected in 2H22.","Phase 2b VOYAGE trial of VK2809 for NASH continuing enrollment; initial data expected by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409166,"accession_number":"0001564590-21-053950","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.","Cash, cash equivalents and short-term investments of $216.1M as of Sept 30, 2021 ($248.4M at Dec 31, 2020).","Phase 2b VOYAGE trial for VK2809 (NASH) enrolling; initial data expected in 2022.","Phase 1b trial of VK0214 in X-ALD (AMN) underway; top-line results expected in 2022.","Preclinical dual GLP-1/GIP agonists showed up to 27% body weight reduction; clinical development planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428091,"accession_number":"0001564590-21-038678","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2021-07-28T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Viking Therapeutics enters $125M ATM equity offering; terminates prior $75M facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $125M ATM agreement with Stifel, Truist, and H.C. Wainwright for common stock sales at market prices.","Agents receive 3.0% commission on gross proceeds from sales under the new ATM facility.","Proceeds to fund continued development of VK2809 and VK0214 programs and general corporate purposes.","Terminated prior $75M ATM agreement (Aug 2019) with Stifel and Oppenheimer; no shares ever sold under that facility.","Registration statement for the $125M offering filed but not yet effective; shares may not be sold until effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428090,"accession_number":"0001564590-21-038623","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2021-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking reports Q2 net loss of $15.4M, cash $228.3M; VK2809 VOYAGE enrollment continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $15.4M ($0.20/sh) vs $9.6M ($0.13/sh) in Q2 2020; R&D expenses rose to $12.8M from $7.8M.","Cash, equivalents and short-term investments $228.3M at June 30, down from $248.4M at Dec 31, 2020.","Phase 2b VOYAGE study of VK2809 for NASH enrolling; top-line data expected in 2022.","VK0214 Phase 1 met primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.","Six-month net loss $29.4M ($0.38/sh) vs $19.3M ($0.27/sh) in H1 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}